Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Long-term outcomes of a presbyopic LASIK algorithm used in pseudophakic eyes

Poster Details

First Author: R. Ang PHILIPPINES

Co Author(s):                        

Abstract Details

Purpose:

To report the long term results of a prospective clinical evaluation on the safety and efficacy of a presbyopic Lasik treatment used in pseudophakic patients to improve their near vision.

Setting:

Asian Eye Institute, Philippines

Methods:

30 patients implanted with monofocal intraocular lenses underwent monolateral presbyopic Lasik treatment (Supracor, Bausch and Lomb) on the non-dominant eye. The Supracor software creates a 12-micron elevation with negative spherical aberration in the central cornea surrounded by an aspheric optimized mid-peripheral zone. The central hyperprolate area extends the depth of focus approximately equal to 2.0D of near addition. Subject inclusion criteria are patient age of over 45 years, refractive error -2.0D to +2.0D, cylinder <2.0D and BCDVA of at least 20/25. Measured outcomes included manifest refraction, UDVA, UIVA, UNVA, BCDVA and DCNVA. Target refraction was -0.50D.

Results:

Preoperatively, mean MRSE was +0.23D with mean UDVA of 20/30, UIVA of 20/40 and UNVA of J7. At 2 years, mean MRSE was -0.58D. Mean monocular UDVA, UIVA and UNVA in the study eye improved to 20/25, 20/20 and J2 respectively. Mean BDVA was 20/20 while mean DCNVA was J3. Binocular UDVA was 20/20 and UNVA was J2. One eye lost 1 line and 2 eyes lost 2 lines of BDVA. Two eyes underwent enhancement while one eye had a reversal treatment.

Conclusions:

The study outcomes indicate that the Supracor LASIK algorithm is safe and effective in pseudophakic patients implanted with a monofocal IOL. The treatment provides improved uncorrected near and intermediate vision, while maintaining or improving uncorrected distance vision.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, One or more of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One or more of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing